Sanofi India Reports Quarterly Results While Announcing Key Governance Changes
Sanofi India Limited announced its financial results for the quarter ended March 31, 2026. The company also utilized its Board meeting to announce key governance updates, including changes in directorship and the reconstitution of several board committees.The financial data for the quarter showed revenue growth in the domestic market, while management noted that overall results were affected by transactions related to partnership transitions.
Financial Performance Overview
The company provided the Statement of Unaudited Financial Results for the quarter ended March 31, 2026, along with comparative figures.The financial results in millions of Indian Rupees are presented below:
| Particulars | Quarter ended 31.03.2026 (Unaudited) | Quarter ended 31.12.2025 (Unaudited) | Quarter ended 31.03.2025 (Unaudited) | Year ended 31.12.2025 (Audited) |
|---|---|---|---|---|
| Revenue from Operations | 4,723 | 4,198 | 5,359 | 18,374 |
| Total Income (Revenue + Other Income) | 4,767 | 4,226 | 5,392 | 18,571 |
| Total Expenses | 3,388 | 3,396 | 3,739 | 13,851 |
| Profit before tax | 1,379 | 830 | 1,653 | 4,720 |
| Profit for the period | 1,026 | 617 | 1,195 | 3,267 |
| Basic and diluted earnings per share (in ₹) | 44.55 | 26.79 | 51.89 | 141.85 |
Strategic Market Updates
In the domestic market, the Insulin portfolio delivered double-digit growth for the second consecutive quarter, demonstrating Sanofi’s established equity in the Diabetes Injectable segment. The company also noted that its strategic partnerships across Cardiovascular (CV), Oral anti Diabetes (OAD), and Central Nervous System (CNS) segments established a robust foundation.Deepak Arora, Managing Director, highlighted the importance of the product line, stating, "Despite current focus on newer diabetes therapies, our 14% registered growth (vs previous quarter) and 19% registered growth (vs last year) validates what clinical guidelines consistently affirm: insulin remains essential for comprehensive diabetes care."
Arora added that the company remains committed to driving operational excellence while broadening access to both established and innovative therapies throughout India.
Governance and Committee Restructuring
During the board meeting on April 28, 2026, the company noted the completion of tenure for Mr. Aditya Narayan and Mrs. Usha Thorat as Independent Directors, effective from the close of business hours on Wednesday, April 29, 2026.Furthermore, Mr. Rahul Bhatnagar, Independent Director, was appointed as the Chairman of the Board with effect from Thursday, April 30, 2026.
The board also approved the reconstitution of several key committees, effective from Thursday, April 30, 2026.
Re-constituted Committees:
Audit Committee
| Member Name | Category | Position |
|---|---|---|
| Mrs. Rajani Kesari | Independent Director | Chairperson |
| Mr. Siraj Chaudhry | Independent Director | Member |
| Mr. Vaibhav Karandikar | Non-Executive Director | Member |
Nomination and Remuneration Committee
| Member Name | Category | Position |
|---|---|---|
| Mr. Siraj Chaudhry | Independent Director | Chairman |
| Mrs. Rajani Kesari | Independent Director | Member |
| Mr. Eric Mansion | Non-Executive Director | Member |
Stakeholders Relationship Committee
| Member Name | Category | Position |
|---|---|---|
| Mr. Siraj Chaudhry | Independent Director | Chairman |
| Mr. Deepak Arora | Managing Director | Member |
| Mr. Rachid Ayari | Whole-Time Director and CFO | Member |
Risk Management Committee
| Member Name | Category | Position |
|---|---|---|
| Mrs. Rajani Kesari | Independent Director | Chairperson |
| Mr. Siraj Chaudhry | Independent Director | Member |
| Mr. Rachid Ayari | Whole-Time Director and CFO | Member |
| Mr. Mahadev Gawade | Executive Director | Member |
| Mr. Deepak Arora | Managing Director | Member |
Corporate Social Responsibility Committee
| Member Name | Category | Position |
|---|---|---|
| Mr. Siraj Chaudhry | Independent Director | Chairman |
| Mrs. Rajani Kesari | Independent Director | Member |
| Mr. Deepak Arora | Managing Director | Member |
SANOFI Stock Price Movement
Today, Sanofi India Limited shares edged higher, closing at ₹3469.3 after gaining 0.84% on the back of positive momentum. The equity saw solid investor interest, with 25,760 shares traded during the day.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: